Lexicon Pharmaceuticals | LXRX - Selling And Administration Expenses


Lexicon Pharmaceuticals reported $3.98M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 4.27B 669M Sep/2026
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.12B 305M Sep/2026
Halozyme Therapeutics USD 58.24M 1.24M Sep/2026
Illumina USD 281M 8M Sep/2026
Insmed USD 253.03M 5.56M Sep/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 6.25B 168M Sep/2026
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
MacroGenics USD 7.9M 1.81M Jun/2026
MannKind USD 61.41M 3.11M Sep/2026
Merck USD 2.86B 25M Sep/2026
Moderna USD 282M 66M Sep/2026
Novartis USD 3.08B 163M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Thermo Fisher Scientific USD 1.86B 46M Sep/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
United Therapeutics USD 184.1M 22.6M Sep/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024